How big is Accuray, Inc.?

As of Jun 24, Accuray, Inc. has a market capitalization of 126.71 million, with net sales of 465.25 million and a net profit of 0.68 million over the latest four quarters. Shareholder's funds are 45.08 million, and total assets are 468.63 million.

As of Jun 18, Accuray, Inc. has a market capitalization of 126.71 million, classifying it as a Micro Cap company.<BR><BR>As of Jun 24, the sum of net sales for the latest four quarters is 465.25 million, while the sum of net profit for the same period is 0.68 million.<BR><BR>As of Jun 24, the shareholder's funds amount to 45.08 million, and total assets are reported at 468.63 million.

What does Accuray, Inc. do?

Accuray, Inc. is a micro-cap radiation oncology company that develops and markets medical devices for cancer treatment, with recent net sales of $113 million and a market cap of $126.71 million. As of March 2025, the company reported a net profit of -$1 million and has a debt-to-equity ratio of 2.06.

Overview:<BR>Accuray, Inc. is a radiation oncology company that develops, manufactures, and markets medical devices for cancer treatment, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 113 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 126.71 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 2.06 <BR>Return on Equity: -0.73% <BR>Price to Book: 2.56<BR><BR>Contact Details:<BR>Address: 1310 Chesapeake Ter, SUNNYVALE CA: 94089-1100 <BR>Tel: 1 408 7164600, 1 602 7177804 <BR>Fax: 1 408 7164601 <BR>Website: http://www.accuray.com/

Who are in the management team of Accuray, Inc.?

As of March 2022, Accuray, Inc.'s management team includes CEO Joshua Levine and Independent Chairperson Louis Lavigne, along with several independent directors: Elizabeth Davila, James Hindman, Beverly Huss, Anne Le Grand, and Richard Pettingill.

As of March 2022, the management team of Accuray, Inc. includes the following individuals:<BR><BR>- Mr. Louis Lavigne, who serves as the Independent Chairperson of the Board.<BR>- Mr. Joshua Levine, who is the President, Chief Executive Officer, and Director.<BR>- Ms. Elizabeth Davila, who is an Independent Director.<BR>- Mr. James Hindman, who is an Independent Director.<BR>- Ms. Beverly Huss, who is an Independent Director.<BR>- Ms. Anne Le Grand, who is an Independent Director.<BR>- Mr. Richard Pettingill, who is an Independent Director.<BR><BR>In summary, the management team features a mix of leadership roles, including the CEO and several independent directors.

Should I buy, sell or hold Accuray, Inc.?

Is Accuray, Inc. overvalued or undervalued?

As of August 13, 2025, Accuray, Inc. is considered a risky investment due to its overvaluation, indicated by a high Price to Book Value of 2.68, an EV to EBITDA of 14.26, a low ROCE of 6.87%, a negative ROE of -0.73%, and underperformance against the S&P 500 with a year-to-date return of -12.12%.

As of 13 August 2025, the valuation grade for Accuray, Inc. has moved from attractive to risky, indicating a shift in its financial outlook. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 2.68 and an EV to EBITDA of 14.26, which are relatively high compared to its peers. Additionally, the company's Return on Capital Employed (ROCE) stands at a modest 6.87%, while its Return on Equity (ROE) is negative at -0.73%, further highlighting its financial struggles.<BR><BR>In comparison to its peers, Accuray's EV to EBITDA ratio of 14.26 is significantly lower than that of AngioDynamics, Inc. at 226.06, but higher than Tactile Systems Technology, Inc. at 9.59, which is rated fair. The stock has underperformed against the S&P 500 over multiple periods, with a year-to-date return of -12.12% compared to the S&P 500's 12.22%. This underperformance reinforces the notion that Accuray is not a favorable investment at its current valuation.

Is Accuray, Inc. technically bullish or bearish?

As of July 8, 2025, Accuray, Inc. is in a mildly bearish trend, with mixed technical indicators and underperformance compared to the S&P 500, showing a year-to-date return of -12.12% versus the S&P's 12.22%.

As of 8 July 2025, the technical trend for Accuray, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD is mildly bullish on the weekly chart but bearish on the monthly, while the RSI is bearish on the weekly and shows no signal on the monthly. Moving averages indicate a mildly bearish trend on the daily timeframe. Bollinger Bands are bullish weekly but mildly bearish monthly. KST and Dow Theory both show mildly bullish signals on the weekly and monthly charts.<BR><BR>In terms of performance, Accuray has underperformed the S&P 500 across multiple periods, with a year-to-date return of -12.12% compared to the S&P 500's 12.22%, and a 1-year return of -8.90% versus 17.14% for the benchmark.